Tytor M, Gemryd P, Grenko R, Lundgren J, Lundquist P G, Nordenskjöld B
Department of Otolaryngology/Head & Neck Surgery, University Hospital, Linköping, Sweden.
Head Neck. 1995 Jul-Aug;17(4):319-27. doi: 10.1002/hed.2880170408.
DNA ploidy pattern is sometimes used as a prognostic factor. Heterogeneity of a tumor could, however, give false information when a single analysis is performed.
Twenty-eight patients with adenoid cystic carcinomas were retrospectively studied with regard to clinico-histologic parameters, and in 24 of these the DNA pattern was assessed using flow cytometry, with multiple analysis from different tumor parts, to determine prognostic factors.
Of the carcinomas, 33% (8/24) were DNA aneuploid, and 17% (4/24) of the tumors showed intratumoral heterogeneity of DNA content; two of them with mixture of diploid and aneuploid stemlines. The DNA aneuploid tumors were clinically more advanced and demonstrated a higher frequency of solid architecture than did diploid tumors (p < 0.05). The S-phase values were significantly higher in aneuploid samples than in diploid ones (p < 0.05). The recurrence rate was significantly higher in patients with aneuploid tumors (75%) than with diploid ones (19%) (p < 0.05). The cumulative survival was worse for patients with aneuploid tumors than for those with diploid ones (p < 0.05).
Our findings suggest a potentially important role for flow cytometry in evaluation of adenoid cystic carcinoma. It is of interest to observe that in some tumors both diploid and aneuploid stemlines can co-exist. If one sample is analyzed and demonstrates diploid cells, there is a 3% chance that the tumor is also heterogeneous with aneuploid stemlines. If one sample demonstrates aneuploid cells, there is a 7% chance for heterogeneity with diploid cells, as well. Two samples from different tumor parts can be considered representative.
DNA倍体模式有时被用作预后因素。然而，当进行单一分析时，肿瘤的异质性可能会给出错误信息。
回顾性研究了28例腺样囊性癌患者的临床组织学参数，其中24例使用流式细胞术评估DNA模式，对不同肿瘤部位进行多次分析，以确定预后因素。
在这些癌中，33%（8/24）为DNA非整倍体，17%（4/24）的肿瘤显示DNA含量的瘤内异质性；其中两例为二倍体和非整倍体干细胞系的混合。DNA非整倍体肿瘤在临床上更晚期，与二倍体肿瘤相比，实体结构的频率更高（p<0.05）。非整倍体样本的S期值显著高于二倍体样本（p<0.05）。非整倍体肿瘤患者的复发率（75%）显著高于二倍体肿瘤患者（19%）（p<0.05）。非整倍体肿瘤患者的累积生存率低于二倍体肿瘤患者（p<0.05）。
我们的研究结果表明流式细胞术在腺样囊性癌评估中可能具有重要作用。有趣的是，观察到在一些肿瘤中二倍体和非整倍体干细胞系可以共存。如果分析一个样本并显示为二倍体细胞，那么该肿瘤也存在非整倍体干细胞系异质性的可能性为3%。如果一个样本显示为非整倍体细胞，那么也有7%的可能性存在二倍体细胞异质性。来自不同肿瘤部位的两个样本可被视为具有代表性。
